0001854817-21-000003.txt : 20211216 0001854817-21-000003.hdr.sgml : 20211216 20211216164248 ACCESSION NUMBER: 0001854817-21-000003 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20211216 DATE AS OF CHANGE: 20211216 EFFECTIVENESS DATE: 20211216 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NOFUSCO Corp CENTRAL INDEX KEY: 0001854817 IRS NUMBER: 862379034 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-425418 FILM NUMBER: 211498243 BUSINESS ADDRESS: STREET 1: 3430 WILD OAK BAY BOULEVARD STREET 2: UNIT 123 CITY: BRADENTON STATE: FL ZIP: 34210 BUSINESS PHONE: 2153844500 MAIL ADDRESS: STREET 1: 3430 WILD OAK BAY BOULEVARD STREET 2: UNIT 123 CITY: BRADENTON STATE: FL ZIP: 34210 D 1 primary_doc.xml X0708 D LIVE 0001854817 NOFUSCO Corp 3430 WILD OAK BAY BOULEVARD UNIT 123 BRADENTON FL FLORIDA 34210 2153844500 DELAWARE None None Corporation true 2021 Randal R Betz 3430 Wild Oak Bay Boulevard Unit 123 Bradenton FL FLORIDA 34210 Executive Officer Director Promoter Dale Whipple 12 Hibiscus Way Nashua NH NEW HAMPSHIRE 03062 Executive Officer Director Thomas Raymond 9523 Cypress Hammock Cr # 202 Bonita Springs FL FLORIDA 34135 Executive Officer Director Marc Burel 1926 Broad Street Perkasie PA PENNSYLVANIA 18944 Director Michael Dalesio 700 Pheasant Run West Chester PA PENNSYLVANIA 19382 Director Other Health Care No Revenues 06b false 2021-12-02 false true true true true true Convertible Promissory Note false 200000 Centerboard Securities, LLC 15390 None None 9430 RESEARCH BLVD Suite 120 AUSTIN TX TEXAS 78759 NY NEW YORK false 4000000 2100000 1900000 This filing covers the purchase and sale of Convertible Promissory Notes, the Preferred Stock issuable upon conversion of such Notes and the Common Stock issuable upon the conversion of such Preferred Stock. true 0 5 0 0 150000 true Reimbursing Randal Betz for patent, legal and marketing fees expended on behalf of the company, and engaging Dale Whipple as a consultant at a fee of $5,000 per month to complete FDA approval. false NOFUSCO Corp /s/ Randal R. Betz /s/ Randal R. Betz President 2021-12-16